Last 7 days
-4.8%
Last 30 days
-0.1%
Last 90 days
8.6%
Trailing 12 Months
27.2%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
SYK | 110.8B | 19.0B | -8.78% | 16.43% | 46.98 | 6.01 | 8.73% | 30.37% |
ISRG | 107.5B | 6.4B | 4.05% | 37.44% | 81.96 | 16.72 | 8.89% | -20.19% |
BSX | 74.1B | 13.0B | -0.08% | 27.20% | 106.12 | 5.84 | 7.26% | -32.95% |
BDX | 71.3B | 18.8B | -6.73% | -3.13% | 44.09 | 3.79 | -1.96% | -15.83% |
EW | 49.7B | 5.5B | -6.18% | -16.80% | 33.38 | 9.03 | 2.68% | -3.23% |
MID-CAP | ||||||||
SWAV | 7.2T | 557.2M | -1.64% | 66.40% | 82.2K | 16.8K | 86.42% | 730.06% |
PEN | 11.7B | 884.6M | 7.85% | 115.97% | 1.8K | 13.2 | 13.08% | 200.12% |
GMED | 5.9B | 1.1B | -8.20% | -19.98% | 34.14 | 5.75 | 11.20% | 53.04% |
IRTC | 3.6B | 430.0M | -11.89% | -12.63% | -34.73 | 8.45 | 26.13% | 15.73% |
TNDM | 1.7B | 794.7M | -29.15% | -60.56% | -8.43 | 2.16 | 7.73% | -3556.34% |
SMALL-CAP | ||||||||
ATEC | 1.6B | 389.0M | -3.76% | 82.19% | -10.63 | 4.18 | 44.08% | 6.96% |
SILK | 1.2B | 150.7M | -30.80% | 0.49% | -21.65 | 7.87 | 40.31% | 1.80% |
AVNS | 1.1B | 814.3M | -20.14% | -16.22% | 24.47 | 1.34 | 6.96% | 121.89% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 2.9% | 13,045 | 12,682 | 12,567 | 12,329 | 12,162 |
Gross Profit | 3.2% | 9,005 | 8,727 | 8,650 | 8,491 | 8,390 |
Operating Expenses | 2.7% | 7,270 | 7,078 | 7,223 | 7,035 | 7,095 |
S&GA Expenses | 3.4% | 4,675 | 4,520 | 4,510 | 4,444 | 4,400 |
EBITDA | 10.3% | 2,747 | 2,490 | 2,739 | 2,544 | - |
EBITDA Margin | 9.3% | 0.22* | 0.20* | 0.22* | 0.21* | - |
Earnings Before Taxes | 25.3% | 1,430 | 1,141 | 865 | 1,103 | 907 |
EBT Margin | 30.7% | 0.09* | 0.07* | 0.09* | 0.07* | - |
Interest Expenses | -45.5% | 256 | 470 | 493 | 516 | 538 |
Net Income | 6.9% | 698 | 653 | 884 | 810 | - |
Net Income Margin | 5.9% | 0.06* | 0.05* | 0.07* | 0.07* | - |
Free Cahsflow | 69.0% | 938 | 555 | 593 | 928 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | 1.3% | 32,892 | 32,469 | 31,947 | 32,189 | 32,337 |
Current Assets | -1.0% | 5,704 | 5,760 | 5,144 | 5,083 | 5,065 |
Cash Equivalents | -17.8% | 763 | 928 | 338 | 276 | 325 |
Inventory | 9.8% | 2,050 | 1,867 | 1,788 | 1,752 | 1,736 |
Net PPE | 1.3% | 2,478 | 2,446 | 2,273 | 2,246 | 2,265 |
Goodwill | 2.7% | 13,269 | 12,920 | 12,852 | 12,883 | 12,949 |
Current Liabilities | 7.4% | 4,083 | 3,803 | 3,549 | 3,883 | 4,275 |
Long Term Debt | -4.7% | 8,495 | 8,915 | 8,564 | 8,802 | 9,067 |
Shareholder's Equity | 3.1% | 18,109 | 17,573 | 17,640 | 17,251 | 16,735 |
Retained Earnings | 40.0% | -450 | -750 | -876 | -1,050 | -1,296 |
Additional Paid-In Capital | 0.3% | 20,356 | 20,289 | 20,219 | 20,103 | 20,043 |
Shares Outstanding | 0.1% | 1,432 | 1,430 | 1,428 | - | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | 16.3% | 1,774 | 1,526 | 1,197 | 1,192 | 1,528 |
Share Based Compensation | 1.4% | 223 | 220 | 214 | 207 | 199 |
Cashflow From Investing | 54.2% | -921 | -2,011 | -2,289 | -3,271 | -3,242 |
Cashflow From Financing | -11.5% | -611 | -548 | -557 | -352 | -6.00 |
Dividend Payments | 0% | 55.00 | 55.00 | 55.00 | 55.00 | 55.00 |
Buy Backs | - | 0.00 | - | - | - | - |
35.4%
18.5%
16.1%
Y-axis is the maximum loss one would have experienced if Boston Scientific was unfortunately bought at previous high price.
18.7%
12.4%
11.0%
12.2%
FIve years rolling returns for Boston Scientific.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | Toroso Investments, LLC | added | 114 | 3,805,000 | 6,688,000 | 0.11% |
2023-05-23 | Front Row Advisors LLC | unchanged | - | 1,000 | 15,000 | 0.01% |
2023-05-23 | Brookfield Corp /ON/ | reduced | -48.11 | -8,412,860 | 10,754,900 | 0.04% |
2023-05-22 | Raleigh Capital Management Inc. | new | - | 135,281 | 135,281 | 0.07% |
2023-05-22 | Westover Capital Advisors, LLC | reduced | -7.01 | 4,739 | 863,418 | 0.32% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -1.54 | 338,753 | 10,484,800 | 0.02% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 415,000 | 0.02% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -33.83 | -94,343,800 | 237,236,000 | 0.38% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -12.44 | -4,900,380 | 55,631,600 | 0.02% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -0.85 | 32,526,500 | 483,597,000 | 0.16% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | blackrock inc. | 9.6% | 137,802,646 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.29% | 118,773,794 | SC 13G/A | |
Feb 08, 2023 | massachusetts financial services co /ma/ | 5.8% | 82,467,469 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 4.03% | 57,736,340 | SC 13G/A | |
Jan 24, 2023 | blackrock inc. | 9.8% | 140,116,265 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 7.83% | 111,621,630 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G | |
Feb 08, 2022 | blackrock inc. | 9.0% | 127,917,655 | SC 13G/A | |
Feb 04, 2022 | wellington management group llp | 5.22% | 74,421,509 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 25, 2023 | SD | SD | |
May 23, 2023 | 144 | Notice of Insider Sale Intent | |
May 17, 2023 | 4 | Insider Trading | |
May 17, 2023 | 4 | Insider Trading | |
May 16, 2023 | 144 | Notice of Insider Sale Intent | |
May 15, 2023 | 144 | Notice of Insider Sale Intent | |
May 09, 2023 | 8-K | Current Report | |
May 05, 2023 | 4 | Insider Trading | |
May 05, 2023 | 4 | Insider Trading | |
May 05, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-16 | Fitzgerald Joseph Michael | sold | -3,394,860 | 53.5982 | -63,339 | evp & group pres, cardiology |
2023-05-16 | Fitzgerald Joseph Michael | acquired | 744,527 | 13.08 | 56,921 | evp & group pres, cardiology |
2023-05-15 | Carruthers Wendy | sold | -624,333 | 53.4944 | -11,671 | evp, human resources |
2023-05-15 | Carruthers Wendy | acquired | 94,953 | 14.818 | 6,408 | evp, human resources |
2023-05-04 | Sununu John E | acquired | - | - | 3,946 | - |
2023-05-04 | Zane Ellen M | acquired | - | - | 3,946 | - |
2023-05-04 | Connors Nelda J | acquired | - | - | 3,946 | - |
2023-05-04 | WICHMANN DAVID S | acquired | - | - | 3,946 | - |
2023-05-04 | Dockendorff Charles J | acquired | - | - | 3,946 | - |
2023-05-04 | ROUX DAVID J | acquired | - | - | 3,946 | - |
Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Net sales | $ 3,389 | $ 3,026 |
Cost of products sold | 1,040 | 955 |
Gross profit | 2,349 | 2,071 |
Operating expenses: | ||
Selling, general and administrative expenses | 1,215 | 1,060 |
Research and development expenses | 337 | 319 |
Royalty expense | 11 | 12 |
Amortization expense | 203 | 198 |
Contingent consideration net expense (benefit) | 12 | 12 |
Restructuring net charges (credits) | 20 | 4 |
Operating expenses | 1,797 | 1,605 |
Operating income (loss) | 552 | 466 |
Other income (expense): | ||
Interest expense | (65) | (279) |
Other, net | (43) | (31) |
Income (loss) before income taxes | 444 | 156 |
Income tax expense (benefit) | 131 | 45 |
Net income (loss) | 314 | 110 |
Preferred stock dividends | (14) | (14) |
Net income (loss) attributable to noncontrolling interests | 0 | 0 |
Net income (loss) attributable to Boston Scientific common stockholders | $ 300 | $ 97 |
Net income (loss) per common share — basic | $ 0.21 | $ 0.07 |
Net income (loss) per common share — diluted | $ 0.21 | $ 0.07 |
Weighted-average shares outstanding | ||
Basic | 1,435.8 | 1,427.8 |
Diluted | 1,446.0 | 1,438.4 |
Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 570 | $ 928 |
Trade accounts receivable, net | 2,076 | 1,970 |
Inventories | 2,050 | 1,867 |
Prepaid income taxes | 296 | 264 |
Other current assets | 711 | 731 |
Total current assets | 5,704 | 5,760 |
Property, plant and equipment, net | 2,478 | 2,446 |
Goodwill | 13,269 | 12,920 |
Other intangible assets, net | 6,060 | 5,902 |
Deferred tax assets | 3,900 | 3,942 |
Other long-term assets | 1,482 | 1,500 |
TOTAL ASSETS | 32,892 | 32,469 |
Current liabilities: | ||
Current debt obligations | 510 | 20 |
Accounts payable | 868 | 862 |
Accrued expenses | 1,918 | 2,160 |
Other current liabilities | 787 | 761 |
Total current liabilities | 4,083 | 3,803 |
Long-term debt | 8,495 | 8,915 |
Deferred income taxes | 210 | 144 |
Other long-term liabilities | 1,995 | 2,035 |
Commitments and contingencies | ||
Stockholders’ equity | ||
Preferred stock, $0.01 par value - authorized 50,000,000 shares - issued 10,062,500 shares as of March 31, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,700,828,873 shares as of March 31, 2023 and 1,696,633,993 shares as of December 31, 2022 | 17 | 17 |
Treasury stock, at cost - 263,289,848 shares as of March 31, 2023 and December 31, 2022 | (2,251) | (2,251) |
Additional paid-in capital | 20,356 | 20,289 |
Accumulated deficit | (450) | (750) |
Accumulated other comprehensive income (loss), net of tax | 178 | 269 |
Total stockholders’ equity | 17,850 | 17,573 |
Noncontrolling interests | 259 | 0 |
Total equity | 18,109 | 17,573 |
TOTAL LIABILITIES AND EQUITY | $ 32,892 | $ 32,469 |